Compare RRC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRC | MDGL |
|---|---|---|
| Founded | 1976 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 11.5B |
| IPO Year | 1996 | 2005 |
| Metric | RRC | MDGL |
|---|---|---|
| Price | $41.17 | $518.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | $43.67 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 2.3M | 264.2K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 151.38 | 41.32 |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $3,115,515,000.00 | $180,133,000.00 |
| Revenue This Year | $15.60 | $58.39 |
| Revenue Next Year | $9.73 | $48.55 |
| P/E Ratio | $28.50 | ★ N/A |
| Revenue Growth | ★ 28.90 | N/A |
| 52 Week Low | $32.60 | $265.00 |
| 52 Week High | $48.31 | $615.00 |
| Indicator | RRC | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 51.29 |
| Support Level | $40.16 | $498.34 |
| Resistance Level | $44.24 | $554.40 |
| Average True Range (ATR) | 1.02 | 23.54 |
| MACD | -0.00 | -1.47 |
| Stochastic Oscillator | 36.68 | 41.89 |
Range Resources is an exploration and production firm whose operations represent a pure play in the Marcellus shale, located in the Appalachian region of Southwest Pennsylvania. The company went public as Lomak Petroleum in 1980 and later reorganized as Range Resources in 1998. After an expensive 10-year venture with a multi-basin strategy, Range Resources found its identity as an Appalachian natural gas producer, offloading its Permian assets in 2013. Range quickly became a leading US gas producer after its merger with Memorial Resource Development in 2016. Following the merger, Range saw its operational unit costs rise to an uncompetitive level and subsequently sold the assets in 2020 to return to its roots as an Appalachian producer.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.